Stockscreener 앱 받기
3.0801
2.28%
0.0101
전일 마감가:
$3.07
열려 있는:
$3.09
하루 거래량:
2,031
Relative Volume:
0.01
시가총액:
$3.03M
수익:
$7.68M
순이익/손실:
$-34.33M
주가수익비율:
-0.0349
EPS:
-88.1566
순현금흐름:
$-19.17M
1주 성능:
-11.05%
1개월 성능:
-46.23%
6개월 성능:
-80.46%
1년 성능:
-93.05%
1일 변동 폭
$3.08
$3.09
1주일 범위
$3.063
$3.58
52주 변동 폭
$3.063
$55.60
Beyond Air Inc Stock (XAIR) Company Profile
명칭
Beyond Air Inc
전화
516-665-8200
주소
900 STEWART AVENUE, GARDEN CITY, NY
Compare XAIR vs ABT, MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XAIR
Beyond Air Inc
|
3.08 | 3.02M | 7.68M | -34.33M | -19.17M | -88.16 |
ABT
Abbott Laboratories
|
103.57 | 178.85B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
92.24 | 117.19B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
271.19 | 103.57B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.44 | 62.46B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.42 | 50.01B | 6.30B | 1.07B | 1.09B | 1.8406 |
Beyond Air Inc Stock (XAIR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-17 | 개시 | D. Boral Capital | Buy |
| 2024-06-25 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-07-28 | 개시 | Piper Sandler | Overweight |
| 2023-06-15 | 개시 | BTIG Research | Buy |
| 2021-04-28 | 개시 | Truist | Buy |
| 2019-10-22 | 개시 | Oppenheimer | Outperform |
모두보기
Beyond Air Inc 주식(XAIR)의 최신 뉴스
XAIR: Generation 2 device approval is set to unlock a $400M+ market with immediate deployment planned - TradingView
Beyond Air at cantors conference: generation 2 is the focus By Investing.com - Investing.com Canada
XAIR: Generation 2 enables immediate entry into the $400M U.S. transport market upon FDA approval - TradingView
Beyond Air at cantors conference: generation 2 is the focus - Investing.com India
Lucid, Beyond Air, Conagra Stocks Hit 52-Week Lows: What's Behind The Drag? - Stocktwits
Beyond Air Inc (NASDAQ: XAIR) Share Price, XAIR Stock News, XAIR Share Price & Updates - Kalkine
At the Waldorf Astoria, Beyond Air joins a healthcare conference Sept. 10 - Stock Titan
XAIR Initiates Coverage On Beyond Air -- Rating Set to Buy - GuruFocus
Lake Street Initiates Beyond Air at Buy With $10 Price Target - marketscreener.com
XAIR Looks 98.9% Undervalued on GF Value™ Despite Financial Stru - GuruFocus
Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) - The Manila Times
Beyond Air Announces FDA Breakthrough Device Designation for LungFit GO in NTM-PD Treatment - Quiver Quantitative
A portable treatment for hard-to-treat lung infections gets FDA breakthrough status - Stock Titan
Beyond Air to Sell NeuroNOS Stake to UNIVO in Equity, Milestone Deal - citybiz
Beyond Air to sell NeuroNOS stake to Univo for 19.99% equity By Investing.com - Investing.com Nigeria
Beyond Air to sell NeuroNOS stake to Univo for 19.99% equity - Investing.com India
Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments - Yahoo Finance
Balyasny Asset Management L.P. Buys Beyond Air Inc (XAIR) -- Sha - GuruFocus
Beyond Air Inc (XAIR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Beyond Air | 8-K: Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update - Moomoo
Form 8K Beyond Air Inc For: 18 August By Investing.com - Investing.com Nigeria
Beyond Air (NASDAQ: XAIR) resale may lift share count to 6.2M - Stock Titan
Beyond Air Q2 net loss hits USD 7.9M - Medical Buyer
Cash per share of Beyond Air, Inc. – FWB:48L - TradingView
Beyond Air Inc (XAIR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
XAIR Q2 2026 Earnings: Narrower Loss Fails to Stem 8.74% Stock DeclineEarnings Sentiment Score - vinanet.vn
Beyond Air Sticks to Revenue Targets as LungFit PH Gen II FDA Decision Nears - finance.biggo.com
Beyond Air Inc (XAIR) Stock News Today - TradingKey
Beyond Air (XAIR) Surges 14.4% to $6.92 as Bulls Defend SupportRisk Parity Rebalance - vinanet.vn
Beyond Air (XAIR) gains 5.30% beneficial owner as Balyasny Asset Management reports 763,266 shares - Stock Titan
XAIR|Beyond Air Inc|Price:7.160|Chg%:+1.110 - TradingKey
Beyond Air (XAIR) Earnings Call zum 1. Quartal des Geschäftsjahres 2027: FDA-Katalysator, Ausblick von 8 Mio. USD für 2026 - TradingKey
Beyond Air (XAIR) Fiscal Q1 2027 Earnings Call: FDA Catalyst, $8M 2026 Outlook - TradingKey
Beyond Air earnings missed by $0.10, revenue fell short of estimates - Investing.com Canada
Beyond Air (XAIR) Q1 2027 Earnings Call Transcript - AOL.com
Beyond Air Inc (XAIR) (Q1 2027) Earnings Call Highlights: Strate - GuruFocus
Beyond Air Inc (XAIR) (Q1 2027) Earnings Call Highlights: Strategic Financing and Pipeline ... - Yahoo Finance UK
Beyond Air, Inc. Q1 2027 Earnings Call Summary - Yahoo Finance
Beyond Air (XAIR) posts $7.9M loss and cites funding risk in quarter - Stock Titan
Beyond Air, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026 - marketscreener.com
Beyond Air Releases Q1 2027 Financial Results - AlphaStreet
XAIR: Gross margin rose to 13% as pipeline doubled and 2026 revenue guidance was reaffirmed at $8M - TradingView
Beyond Air Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Beyond Air misses Q1 2027 revenue view, shares fall premarket - Investing.com
Beyond Air Q1 Results: EPS Misses Estimate, Sales Flat YoY - scanx.trade
Beyond Air Q1 FY27 net loss widens to $8.15 million; revenue flat at $1.77 million - Bitget
BEYOND AIR ($XAIR) Releases Q1 2027 Earnings - Quiver Quantitative
Beyond Air Q1 net loss slightly widens, reaffirms 2026 outlook - TradingView
Beyond Air Reports $1.8 Million Q2 Revenue, Reaffirms 2026 and 2027 Guidance as FDA Reviews Second-Generation LungFit PH System - Quiver Quantitative
Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update - marketscreener.com
Qubeyond Air, Inc. Reaffirms Earnings Guidance for the for Calendar Year 2026 and for 2027 - marketscreener.com
Beyond Air Inc (XAIR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.41%
1.03%
자본화:
|
볼륨(24시간):